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Abstract
Background Facial lipoatrophy is a stigmatizing hallmark
of HIV. The injection of facial fillers has an essential role
in the treatment of this condition. The objective of our
study was to verify the safety and efficacy of a new for-
mulation of high-density hyaluronic acid for the injectable
treatment of HIV-related facial lipoatrophy.
Methods We treated with high-density hyaluronic acid
injections HIV patients affected by moderate to severe
facial lipoatrophy and evaluated them at last follow-up, at a
minimum of 36 weeks. Physician-related outcomes inclu-
ded pre-and post-treatment ultrasound measurement of the
soft-tissue thickness of the cheeks and qualitative assess-
ment of aesthetic results by means of the Global Aesthetic
Improvement Scale using pre- and post-treatment photos of
the patients. Patient satisfaction outcomes were evaluated
with the VAS-face scale and Freiburg test.
Results Fifty-four patients were studied. The median
number of treatment sessions was 3 and the median length of
treatment was 5.5 months. The thickness of the soft tissues
of the cheek increased significantly from 9.45 to 13.12 mm
(p \ 0.0001). On the basis of the Global Aesthetic
Improvement Scale, 87.5% of the patients were judged as
‘‘much improved’’ or ‘‘improved.’’ Patient satisfaction at
1 year from the end of treatment was proven (VAS-face:
77.9; Freiburg questionnaire: 93.6% of patients were satis-
fied or very satisfied). Complications were limited to mild
redness and swelling in the early postoperative period.
Conclusion Long-term improvement of facial contour
and excellent patient satisfaction, in the absence of severe
side effects, were obtained by the injection of high-density
hyaluronic acid (STYLAGE XL) in HIV patients with
facial lipoatrophy.
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HIV-associated lipodystrophy is a syndrome characterized
by body fat changes, including loss of peripheral fat tissue
(lipoatrophy) typically in the limbs, buttocks, and the face
(facial lipoatrophy, FLA), and frequently, but not neces-
sarily, associated with central fat accumulation (lipohy-
pertrophy). The etiology of the syndrome, although still not
completely clarified, includes antiretroviral therapy (ART),
HIV per se, genetic predisposition, immunologic/inflam-
matory response, and metabolic dysregulation [1]. Lipoat-
rophy is still highly prevalent among these patients even if
the incidence is decreasing thanks to a modification in the
use of the ART drugs [2–4]. Nevertheless, in the FRAM
case control study (Fat Redistribution And Metabolic
change in HIV infection) HIV-associated lipoatrophy was
shown to persist for more than 5 years of follow-up [5].
Facial lipoatrophy (FLA) is a stigmatizing feature of HIV
patients and may compromise their quality of life [6],
causing severe psychological distress, body image impair-
ment, loss of self-esteem, depression, social isolation, sexual
dysfunctions, and career barriers [7]. The thymidine analog
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ART-sparing regimens did not prove to be sufficient, by
themselves, to treat facial lipoatrophy [5]. The injection of
facial fillers, has, therefore, an important role as a comple-
mentary therapeutic intervention [3]. Commonly used fillers
include autologous fat on one side and permanent or
absorbable synthetic materials on the other. Among the
permanent fillers, polymethylmethacrylate, expanded poly-
tetrafluoroethylene implants, polyacrylamide gel, and other
synthetic injectable polymers have been used [8]. Among
absorbable fillers are polylactic acid [9], calcium hydroxy-
apatite, collagen, Alloderm, and hyaluronic acid [1]. Only
two partially randomized studies have been published that
compare different fillers so it is not yet established which
treatment is more adequate [10, 11].
Hyaluronic acid (HA) is the filling material most widely
used [12, 13], especially in cosmetic surgery. It is US FDA-
approved for the correction of facial wrinkles and folds
(Restylane, Medicis Aesthetics, Scottsdale, AZ, USA; and
Hylaform, Inamed Aesthetics, Santa Barbara, CA, USA). It
is safe, has a low complication rate [14], and has the
advantage that its effects are reversible [15]. To increase
durability of volume correction while keeping a low inci-
dence of side effects, large particle and high-density hyal-
uronic acid has been marketed [14, 15]. The use of these
long lasting hyaluronic acid (Restylane SubQ2, and Juva-
derm Voluma, Allergan, Irvine, CA, USA) has recently
been reported for the treatment of HIV facial lipoatrophy
[16–18].
The objective of our study was to describe the safety and
effectiveness of a new formulation of high-density hyalu-
ronic acid filler for the treatment of moderate to severe
HIV-related facial lipoatrophy in a large series of patients
followed for a long period of time.
Methods
An observational study of a series of consecutive patients
treated with HA facial injections for moderate to severe, as
defined by Fontdevila [19], HIV-related facial lipoatrophy
and who reached a minimum of 36 weeks of follow-up was
conducted at the Metabolic Clinic of the University of
Modena and Reggio Emilia. This is a tertiary-level referral
center of the Public National Health System where patients
receive, free of charge, comprehensive metabolic and
anthropometric diagnostic and therapeutic assessments for
the presence of lipodystrophy and HIV-associated comor-
bidities. The multidisciplinary team includes infectious
disease specialists, cardiologists, endocrinologists, radiol-
ogists, nutritionists, personal trainers, psychologists, and
plastic surgeons [20].
Inclusion criteria for the study were HIV-related mod-
erate to severe facial lipoatrophy, adult age, exposure to
highly active antiretroviral therapy for at least 6 months,
platelet count greater than 50,000 cells/L, a minimum of
36 weeks of follow-up from the end of the injection
treatment, and consent to be part of the study. Exclusion
criteria were previous use at the same site of permanent
facial fillers or injection of absorbable fillers within the
previous 6 months, pregnancy, and localized infections of
the face.
A high-density (26 mg/g) HA of nonanimal origin
(STYLAGE XL, Vivacy Laboratoires, Paris, France) was
used. This filler is declared by the manufacturer to be
absorbed in more than 12 months and is indicated to
increase soft tissue volume in any area of the body. The
product is made of two separately reticulated molecular
chains (tight ones and loose ones), interpenetrated with
crosslinks that are not chemical bonds but relatively weak
interactions between the two structures (IPN-like technol-
ogy = InterPenetrated Network), to obtain a dense texture.
The overall structure is monophasic. This composition is
supposed to reduce degradation by hyaluronidase and heat,
therefore increasing durability.
Each patient was treated with the injection of one vial
(1 ml) of STYLAGE XL in each cheek at each monthly
outpatient appointment, until a correction of the facial soft
tissue defect was considered satisfactory by the surgeon,
the infectious disease specialist, and the patient. The
injection was performed with a 27-gauge or a 25-gauge
needle in the subcutaneous tissue using the linear threading
technique and either a fanning or a cross-radial distribution
or both, depending on the patient’s needs [21]. At the end
of each treatment, the injected areas were gently massaged
to optimize the result.
Physician-related Outcomes
Standardized photographs of the face were taken and
ultrasound of the cheek soft tissues was performed in all
patients before starting therapy and at weeks 12, 24, 36,
and 60. Ultrasound examination of the cheeks using a 7.5-
MHz probe was used to record dermal and subcutaneous
thickness, assessed as the average of three readings taken
perpendicular to the skin surface at the nasolabial fold, at
the angle of the mouth, at the zygomatic arch, and centrally
between these points in the area of the buccal fat pad. Final
ultrasound thickness was evaluated at the end of follow-up
and compared with the pre-treatment measurements. To
evaluate the effect of a single treatment session, the results
of the same measurements after the same follow-up inter-
val were evaluated separately in a subgroup of patients who
had received only one treatment.
The pre- and post-treatment photos at 1 year were eval-
uated by three head and neck surgeons (who had not per-
formed the treatment), three nurses, and three nonmedical
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persons. They were requested to judge the appearance of the
patients and express their opinion according to the Global
Aesthetic Improvement Scale (GAIS): ‘‘very much
improved,’’ ‘‘much improved,’’ ‘‘improved,’’ ‘‘no change,’’
or ‘‘worse’’ [22].
Patient-related Outcomes
Patient satisfaction was evaluated by means of the visual
analog scale (VAS)-face and the Freiburg questionnaire.
According to VAS for the face, patients were asked how
they judged their appearance at the time of interview,
expressed as a number from 0 to 100, where 100 was the
best possible appearance. On the basis of the Freiburg
questionnaire on aesthetic dermatology and cosmetic sur-
gery, patients were asked whether the treatment adequately
corrected the defects of their faces and whether they would
suggest this treatment to other patients with the same
problem [18].
Statistical Analysis
The differences of the cheek dermal and subcutaneous
thicknesses measured by ultrasound at baseline and at final
follow-up were analyzed by the Mann–Whitney U test for
the whole cohort and separately for the subgroup which
underwent only one treatment session. Qualitative results
of outcomes as judged by physicians and patients were
analyzed using the v2 test. All statistical analyses were
performed using STATA 10.1 Intercooled (statistics/data
analysis) software for Mac (Stata Corp., College Station,
TX, USA).
Results
Fifty-four (41 males) of the 379 patients treated with at least
one hyaluronic acid injection from June 2008 to December
2009 reached at least 36 weeks of follow-up and were ana-
lyzed in this study. At baseline, the median age was 47 years
(range = 38.4–62.76) and median BMI was 22.27. The
median number of treatment sessions was 3 (range = 1–9)
and median length of treatment was 5.5 months. Ultrasound
measurements showed a median increase in cheek thickness
(dermis plus subcutaneous tissue) of 3.67 mm from a pre-
treatment median value of 9.45 mm (range = 0–15.1) to a
post-treatment median value of 13.12 mm (range =
8.75–18.85) (p \ 0.001) at a minimum follow-up time of
36 weeks (Fig. 1).
In the subgroup of 12 patients who received only one
HA injection (1 ml in each cheek) and who were analyzed
separately, there were 8 males and 4 females with a median
age of 47.2 years (range = 39.9–62.33). The cheek
thickness improved from a pretreatment median value of
7.82 mm (range = 0–14.15) to a post-treatment median
value of 12.25 mm (range = 9.4–15.75), (p = 0.0163)
(Fig. 2). The median BMI was 22.05 pretreatment and
22.56 post-treatment.
Physician-related outcome as judged by the Global
Aesthetic Improvement Scale based on the pretreatment
and 1-year post-treatment photos was ‘‘very much
improved’’ in 27 (50%) patients, ‘‘much improved’’ in 20
(37.5%) patients, and ‘‘improved’’ in 7 (2.5%) patients. No
patient was considered to have worsened after the
treatment.
Patient-related outcome, analyzed by the VAS-face
test in a sample of 47 patients, was very good (77.9).
Answering the Freiburg questionnaire, 9 patients (19.1%)
declared the results to be very satisfactory, 35 patients
Fig. 1 Soft-tissue thickness of the cheeks of all the patients in the
study evaluated with ultrasound. Statistically significant improvement
of thickness at follow-up
Fig. 2 Soft-tissue thickness of the cheeks of the subgroup of patients
treated with one session only. There is statistically significant long-
lasting improvement of soft-tissue thickness of the cheek
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(74.5%) satisfactory, and 3 patients (6.4%) poor. None of
the patients found the results not at all satisfactory (Fig. 3).
All 47 patients (100%) would suggest this treatment to
other patients with the same problem.
Adverse events reported in the follow-up period inclu-
ded mild redness and swelling of different levels of
severity experienced by 70% of patients in the early post-
operative period. Also, tenderness and pain of low intensity
was reported only in the early postoperative period by 11
patients (20.4%). No patient developed a fever. Ten
(18.5%) patients with severe FLA complained, at the time
of the second treatment session, of the presence of non-
visible but palpable lumps. These could be attributed to
subcutaneous deposits of hyaluronic acid in the very thin
soft tissue layer which is typical at the beginning of the
treatment. The subsequent injections in the surrounding
hypotrophic areas corrected this perceived abnormality.
No patient developed skin indurations. One patient
developed a sudden swelling of the treated area after a flu-
like episode 3 months after the end of treatment. However,
no redness or fluid collections were reported and no med-
ical advice was sought. The reported swelling resolved
spontaneously in 2 weeks. No infections or other compli-
cations were encountered.
Figures 4, 5, and 6 show the pre- and post-treatment
photos of patients suffering from FLA of different severity
levels.
Discussion
Facial lipoatrophy in HIV patients has been treated previ-
ously with the injection of permanent or absorbable mate-
rials, including hyaluronic acid, with satisfactory results [1,
8, 9, 17, 18, 23]. The obvious drawback of absorbable fillers
is the need to repeat treatments over time. Recent studies
have shown that large-particle and high-density hyaluronic
acid preparations (Restylane SubQ, Juvaderm Voluma) are
able to safely and efficiently provide correction of the tissue
defect in this kind of patient for a longer time (up to
12 months post-treatment) than the hyaluronic acid prepa-
ration of usual density [16–18].
The efficacy of high-density hyaluronic acid was con-
firmed in our study by the statistically significant improve-
ment in thickness of the dermis-subcutaneous layer of the
cheeks. The BMI variation between the beginning and the
end of treatment, on the other hand, was not statistically
significant and could not be considered responsible for the
change. Our results confirmed also the long-lasting efficacy
Fig. 3 Results of the patient satisfaction evaluation at 1 year from
the end of treatment. Answer to the first question of the Freiburg
questionnaire on aesthetic dermatology and cosmetic surgery: ‘‘Did
the treatment adequately correct the defects of your face?’’
Fig. 4 Photos of a patient suffering from severe FLA. He received six treatment sessions, had a VAS satisfaction of 90, and no complications.
Judged at GAIS (Global Aesthetic Improvement Scale) as ‘‘much improved.’’ Top row Pretreatment. Bottom row At 13 months of follow-up
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of high-density hyaluronic acid, the rarity of complications,
and the satisfaction of the patients (93.6% of 47 patients at
1 year after the end of treatment).
Interestingly, a small number of treatment sessions
appeared to be sufficient to correct the defect. Depending
on the level of severity of FLA and on the self-perception
of each patient, however, the number of treatment sessions
can vary. In our patients between 1 and 9 sessions were
necessary for optimal results.
We decided, per protocol, to inject a maximum amount
of 1 ml in each cheek at each treatment session. Although
previous studies [16] have shown that the volume injected
can be increased, complications such as skin indurations
could also increase, reaching 23% in the study by Skeie
et al. [17], where up to 3 ml of Restylane SubQ was
injected into each cheek at each session. High-density HA
was injected, as suggested by the manufacturer, into the
subcutaneous tissue using a technique similar to the one
used for the HA of lower density.
The results of high-density HA injections in the sub-
group of patients who had only one treatment session
suggest that even a single injection is able to increase the
soft tissue thickness. A statistical analysis trying to corre-
late the surprisingly good results of this subgroup of
patients to their demographic characteristics or therapeutic
regimens was unable to show any significant correlation.
The obvious limitation of these results is the small number
of patients treated only once.
Fig. 5 Photos of a patient suffering from moderate FLA. He had three treatment sessions and had a VAS satisfaction of 80. Judged at GAIS
(Global Aesthetic Improvement Scale) as ‘‘much improved.’’ Top row Pretreatment. Bottom row At 14 months of follow-up
Fig. 6 Photos of a patient suffering from moderate FLA who had one
treatment session, had a VAS satisfaction of 100, and no complica-
tions. Although a noticeable improvement is seen by the authors, this
patient was judged at the GAIS (Global Aesthetic Improvement
Scale) test to be between ‘‘improved’’ and ‘‘no change’’ from
pretreatment. Top row Pretreatment. Bottom row At 12 months of
follow-up
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No patient in our study experienced serious adverse
effects. In particular, no skin indurations requiring the use
of hyaluronidase, as previously described by Skeie et al.
[17], were observed. The only side effects encountered were
mild redness and swelling which resolved spontaneously
and which are normally encountered in cosmetic practice.
In conclusion, this study shows that the injection of the
high-density hyaluronic acid STYLAGE XL is able to
safely and efficiently correct the soft tissue defect of facial
lipoatrophy in HIV patients, with mild side effects and no
major complications. Facial contour was improved for a
long period of time, exceeding in several cases 12 months,
with an excellent rate of patient satisfaction.
Disclosure The authors declare that they have no conflicts of
interest to disclose.
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